Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161958 | 0.90 | DHODH (0.81) | DHODHCYP2D6KCNH2MAPTSIRT1 | |
| SCHEMBL4160505 | 0.85 | DHODH (0.73) | DHODHMAPTLMNAMAPK1SIRT1 | |
| SCHEMBL16433425 | 0.85 | DHODH (0.73) | DHODHLMNAALDH1A1SIRT1HTR2A | |
| SCHEMBL4150775 | 0.83 | DHODH (0.71) | DHODHCYP2D6KCNH2MAPTLMNA | |
| SCHEMBL4157570 | 0.82 | DHODH (0.70) | DHODHCYP2D6SIRT1BRD3MEN1 | |
| SCHEMBL4152198 | 0.82 | DHODH (0.70) | DHODHCYP2D6KCNH2MAPTLMNA | |
| SCHEMBL4165397 | 0.82 | DHODH (0.69) | DHODHCYP2D6KCNH2MAPTLMNA | |
| SCHEMBL4161198 | 0.82 | DHODH (0.69) | DHODHCYP2D6KCNH2MAPTLMNA | |
| SCHEMBL16433416 | 0.82 | DHODH (0.69) | DHODHCYP2D6KCNH2MAPTLMNA | |
| SCHEMBL4151755 | 0.81 | DHODH (0.69) | DHODHCYP2D6KCNH2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271960-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946444-B2 | Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control | PTC THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2013139929-A1 | NOVEL MEANS AND METHODS FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM, METABOLIC AND CARDIAC DISEASES AND AGING | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2013-09-26 | — | — | WO | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | PTC THERAPEUTICS, INC. | 2009-02-12 | — | — | US | disclosed |
| EP-1817025-A2 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC Therapeutics, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006065480-A2 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | PTC THERAPEUTICS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042866-A1 | Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control | VEGFA, FLT4, KDR | DHODH 668/4885CYP2D6 4677/4885KCNH2 4634/4885 |
| US-20150141418-A1 | TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL | VEGFA, FLT4, KDR | DHODH 668/4885CYP2D6 4677/4885KCNH2 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.